Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
0
Authors
Ronan Kelly
Ronan Kelly•Jaffer Ajani•Markus Moehler
Published
March 31, 2021
Abstract
No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.
